News | April 05, 2026
Senores makes bold US push with new federal-focused JV
Company leadership is framing the move as transformational.
Company leadership is framing the move as transformational.
The company said the increase—up to 20%—takes effect immediately, or as current contracts allow
18-year veteran Saharsh will position the CDMO as a premier global API process development and commercial manufacturing specialist
She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River
The CDMO Leadership Awards spotlight top-performing development and manufacturing service providers
The partnership has already launched with five active development programs, with both organizations jointly managing regulatory strategy and documentation under a structured, milestone-gated framework
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
Subscribe To Our Newsletter & Stay Updated
